Brought to you by:
Janssen applies to FDA for new indication to expand use of rivaroxaban in PAD patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a new indication to expand the use of Xarelto (rivaroxaban) in patients with…
New analysis finds DCBs lead to greater four-year survival after fempop revascularization
Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation than those who received treatment using an uncoated device, researchers behind a propensity-matched retrospective review at…
Hodgson: Bringing appropriateness into sharper focus
In 2019, Kim Hodgson, MD, kicked off his presidential year by placing appropriateness and quality of care under the microscope. His turn organizing the E. Stanley Crawford Critical Issues Forum at the 2019 Vascular Annual Meeting (VAM) saw the then…
VA system delivers high quality services for veterans
Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam conflict. Over the years, many have called into question the quality of care within the Veterans…
‘No signal of increased risk of long-term mortality’ with paclitaxel-coated Luminor DCB, EffPac trial finds
An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two years of drug-coated balloon (DCB) angioplasty using a Luminor-35 device (iVascular). This was the conclusion presented by…
Disproportionately more women are affected by depression when pursuing specialty PAD care
A disproportionately higher percentage of women are affected by depressive symptoms when they seek specialty care for new or worsening peripheral arterial disease (PAD) symptoms, with rates almost twice that observed in men, according to a new study published in…
High level of heterogeneity found in randomized PAD trial antithrombotic regimens
A recent systematic review showed that randomized trials comparing different types of peripheral endovascular arterial intervention have a high level of heterogeneity in their antithrombotic regimens. It also revealed an increasing trend for use of dual antiplatelet therapy post intervention…
Diversity, equity and inclusion: Disparities in medicine and vascular surgery
Recent months have yielded a conversation on systemic racism perhaps unlike any other before. We’ve learned about how it manifests across society, how it impacts those on the receiving end, and how it can appear in subtle guises, including in…
‘If I had gone along the path advised, I would never have become a surgeon’
Some of the formative educational experiences described by Olamide Alabi, MD, read like textbook examples of the subtleties many see as baked into U.S. society, multiplying down the years as the very face of systemic racism in the country. These…
Doubted as a doctor during mid-flight medical emergency and once asked: ‘Shouldn’t you be playing basketball?’
In a vascular surgery career spanning 20 years, Vincent Rowe, MD, has seen it all: Tending to patients at bedside, the vascular surgical services chief at Los Angeles County + USC Medical Center has had his very presence as a…